A lab technician inspects filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020.

The European Union announced Thursday it signed a deal with pharmaceutical company Gilead to buy 500,000 treatment courses of Remdesivir, according to reports, an antiviral drug shown to be effective in treating symptoms of coronavirus.

The European Commission, which has overseen joint purchases of vaccines for the European bloc, said there were 37 signatories to the agreement, including all EU countries, six Balkan candidate and potential EU members, Britain and other European Economic Area countries of Iceland, Liechtenstein and Norway, the VOA reported.

While no treatment has proved able to prevent illness after the virus infection, the antiviral drug –known by its commercial name Veklury – has helped COVID-19 patients recover faster.

It is among the drugs being used to treat United States President Donald Trump, who tested positive for coronavirus last week.

According to the drug company, the agreement will allow countries to purchase Remdesivir for immediate use and stockpiling needs.

Author

  • Muhammad Arif Sheva holds a B.A degree in Journalism from Int'l Peace Leadership College Rizal, Philippines. Sheva works as an editor and content writer for Khaama Press.